VolitionRx Limited (NYSEAMERICAN:VNRX) Short Interest Update

VolitionRx Limited (NYSEAMERICAN:VNRX) was the target of a large decline in short interest in the month of March. As of March 15th, there was short interest totalling 507,400 shares, a decline of 13.1% from the February 28th total of 583,700 shares. Based on an average trading volume of 123,100 shares, the short-interest ratio is presently 4.1 days. Approximately 0.9% of the shares of the company are short sold.

VolitionRx Price Performance

Shares of NYSEAMERICAN:VNRX opened at $0.52 on Wednesday. The stock has a market cap of $32.77 million, a price-to-earnings ratio of -0.93 and a beta of 1.59. VolitionRx has a twelve month low of $0.43 and a twelve month high of $1.02.

VolitionRx Company Profile

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes.